Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency

• Autor(a) principal: McGovern, Margaret M.
• Data de Publicação: 2017
• Outros Autores: Vici, Carlo Dionisi, Giugliani, Roberto, Hwu, Paul, Lidove, Olivier, Lukacs, Zoltan, Mengel, Karl Eugen, Mistry, Pramod, Schuchman, Edward, Wasserstein, Melissa P.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/195931
• topic: Guias de prática clínica como assunto; Doenças de Niemann-Pick; Acid sphingomyelin deficiency; Lysosomal storage disorder; Niemann-Pick disease types A and B

Background: Acid sphingomyelinase deficiency (ASMD) is a rare, progressive, and often fatal lysosomal storage disease. The underlying metabolic defect is deficiency of the enzyme acid sphingomyelinase that results in progressive accumulation of sphingomyelin in target tissues. ASMD manifests as a spectrum of severity ranging from rapidly progressive severe neurovisceral disease that is uniformly fatal to more slowly progressive chronic neurovisceral and chronic visceral forms. Disease management is aimed at symptom control and regular assessments for multisystem involvement. Purpose and methods: An international panel of experts in the clinical and laboratory evaluation, diagnosis, treatment/management, and genetic aspects of ASMD convened to review the evidence base and share personal experience in order to develop a guideline for diagnosis of the various ASMD phenotypes. Conclusions: Although care of ASMD patients is typically provided by metabolic disease specialists, the guideline is directed at a wide range of providers because it is important for primary care providers (e.g., pediatricians and internists) and specialists (e.g., pulmonologists, hepatologists, and hematologists) to be able to identify ASMD.